Pharma BD Deal Intelligence
Private equity firm Madison Dearborn Partners scoops up Ikaria for $1.6 billion; existing shareholders led by New Mountain reinvest into a 45% stake in the new…
Ikaria shareholders led by New Mountain Capital agreed to 'sell the Commercial Business to Madison Dearborn Partners in a transaction valued at approximately…
Mallinckrodt agreed to buy Ikaria from the Madison Dearborn-led group for ~$2.3B, validating the LBO thesis on the INOMAX hospital franchise less than…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Madison Dearborn signed definitive agreement for majority ownership of Ikaria in transaction valued ~$1.6B; included separation of Ikaria's outpatient pipeline as spin-out to existing shareholders.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Madison Dearborn Partners / Ikaria, Inc. (this deal) | 2013 | $1.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. | 2025 | $12.0B | 65 |
| Zymeworks Inc. / Theravance Biopharma, Inc. (TD-4208 program) | 2026 | $929M | 63 |
← Browse all deals · How we score deals
More: 2013 deals · Respiratory deals